By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Low PE High Dividend Stocks to Buy Right Now. On March 6, Reuters reported that China has approved Pfizer Inc. (NYSE:PFE)’s GLP-1 treatment Xianweiying ...

China has approved Pfizer's GLP-1 drug Xianweiying for long-term weight management in overweight or obese adults, the U.S. drugmaker said ...

Pfizer China announced that the National Medical Products Administration (NMPA) has officially approved the new-generation ...

China's National Medical Products Administration has approved Pfizer Inc.’s PFE ecnoglutide injection for chronic weight management in adults with overweight or obesity, marking the first approval of ...

Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ecnoglutide, with potential payments ​of up to $495 million if milestones are ‌met, the Chinese drugmaker said ...

Pfizer cuts 2026 revenue forecast as COVID sales fade and patents expire. The firm bets on a monthly obesity drug and ...